Skip to main navigation Skip to search Skip to main content

ENDEAVOR: Randomized, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure with Left

Project: Research

Project Details

StatusFinished
Effective start/end date02/21/22 → 12/31/25

Funding

  • AstraZeneca Pharmaceuticals LP: $99,721.78